← Back to all trials
Active Not Recruiting
NCT03309033
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
Conditions: Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
Sex: Female
Healthy volunteers: Yes
Enrollment: 946
Sponsor: National Cancer Institute (NCI)
Location: Agencia Costarricense de Investigaciones Biomédicas (ACIB) Liberia Guanacaste Province
Summary
This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of women who received three doses. It also studies the stability of HPV defenses in these groups of women for up to 20 years after initial vaccination. Studying samples of blood in the laboratory may provide information on how long one, two, and three doses of the vaccine provide protection against HPV. The results of this study may also help researchers learn whether one dose of HPV vaccine is enough to protect against HPV.
Eligibility Criteria
Inclusion Criteria:
* Participation in the CVT Long Term Follow-Up (LTFU) study
Exclusion Criteria:
* A random subset of the three-dose women
Source: ClinicalTrials.gov (NCT03309033). StuddyBuddy aggregates publicly available trial information.
